Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Aytu Biopharma (AYTU) over the last 8 years, with Q4 2025 value amounting to $81119.0.

  • Aytu Biopharma's Gains from Sales and Divestitures rose 93296.83% to $81119.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $81119.0, marking a year-over-year increase of 93296.83%. This contributed to the annual value of $11193.0 for FY2025, which is 5690.19% down from last year.
  • Per Aytu Biopharma's latest filing, its Gains from Sales and Divestitures stood at $81119.0 for Q4 2025, which was up 93296.83% from $1618.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Gains from Sales and Divestitures registered a high of $642696.0 during Q2 2022, and its lowest value of $1618.0 during Q3 2025.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $28352.0 (2022), whereas its average is $76132.8.
  • As far as peak fluctuations go, Aytu Biopharma's Gains from Sales and Divestitures tumbled by 9339.75% in 2023, and later soared by 93296.83% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's Gains from Sales and Divestitures stood at $90836.0 in 2021, then plummeted by 66.17% to $30733.0 in 2022, then plummeted by 60.34% to $12189.0 in 2023, then tumbled by 35.57% to $7853.0 in 2024, then soared by 932.97% to $81119.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $81119.0 for Q4 2025, versus $1618.0 for Q3 2025 and $11193.0 for Q2 2025.